Posted BY: Jasmine | NwoReport
A recent peer-reviewed study conducted in Peru has revealed promising findings regarding the impact of ivermectin distributions on reducing excess deaths caused by COVID-19. The study, titled ‘COVID-19 Excess Deaths in Peru’s 25 States in 2020: Nationwide Trends, Confounding Factors, and Correlations With the Extent of Ivermectin Treatment by State,’ delved into the effects of intensive ivermectin use on COVID-19 mortality rates.
The research focused on the correlation between ivermectin use and the reduction in excess deaths over a 30-day period following peak mortality rates. The study discovered that in the 10 states with the most intensive administration of ivermectin, there was an average reduction of 74% in excess deaths. Moreover, these reductions closely aligned with the extent of ivermectin utilization across all 25 states studied.
Trending: Jeffrey Epstein, Obama’s White House Counsel, and JPMorgan Chase Linked in Recent Court Filing
During the four months when ivermectin was widely used in 2020, there was a notable 14-fold decrease in nationwide excess deaths. However, following the restriction of ivermectin usage by a new president of Peru, there was a subsequent 13-fold increase in excess deaths within two months. The study acknowledged potential confounding factors, such as social isolation measures, variations in viral strains, and population demographics, but these factors did not seem to significantly impact the observed outcomes. The findings indicated a strong association between ivermectin treatments and a substantial reduction in mortality rates.
The research highlighted the variations in outcomes across different states of Peru, with the most intensive ivermectin distributions showing the sharpest decline in excess deaths. These results were consistent even when accounting for factors like compliance with social isolation measures and varying demographics. In a surprising turn of events, the U.S. Food and Drug Administration (FDA) also reversed its stance on ivermectin, allowing doctors to prescribe it for COVID-19 treatment. This change further underscores the potential significance of the study’s findings and the growing recognition of ivermectin’s role in combating the pandemic.
In conclusion, the study provides compelling evidence that intensive ivermectin use is associated with a significant reduction in COVID-19 excess deaths. The data suggests that widespread distribution of ivermectin could be a valuable strategy in managing the impact of the pandemic, particularly when implemented alongside other preventive measures.
